Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | USP1 | O94782 | 1/20 | 0.35 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13923938 | 0.69 | MEN1 (0.42) | MEN1KMT2ALMNAPOLBALDH1A1 | |
| SCHEMBL3219657 | 0.68 | POLB (0.44) | MEN1KMT2ALMNAPOLBALDH1A1 | |
| SCHEMBL16211049 | 0.65 | MEN1 (1.00) | MEN1KMT2ALMNAPOLBALDH1A1 | |
| SCHEMBL1114753 | 0.64 | — | — | |
| SCHEMBL1114700 | 0.64 | — | — | |
| SCHEMBL1114752 | 0.64 | — | — | |
| SCHEMBL6288849 | 0.64 | ALDH1A1 (0.42) | MEN1KMT2ALMNAPOLBALDH1A1 | |
| SCHEMBL10131913 | 0.64 | MAOA (0.38) | MEN1KMT2ALMNAPOLBL3MBTL1 | |
| SCHEMBL1469805 | 0.64 | CRHBP (0.40) | MEN1KMT2ALMNAPOLBL3MBTL1 | |
| SCHEMBL5936335 | 0.64 | ALDH1A1 (0.42) | MEN1KMT2ALMNAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116135858-B | Furanopyridone compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2025-04-01 | — | — | CN | claimed |
| CN-116135858-A | Furanopyridone compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2023-05-19 | — | — | CN | claimed |
| CN-116135858-B | Furanopyridone compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2025-04-01 | — | — | CN | disclosed |
| WO-2023088493-A1 | FURO-PYRIDONE COMPOUND AND USE THEREOF | 中国科学院广州生物医药与健康研究院 | 2023-05-25 | — | — | WO | disclosed |
| CN-116135858-A | Furanopyridone compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2023-05-19 | — | — | CN | disclosed |
| EP-2279175-B1 | PROCESS FOR THE PREPARATION OF NAPHTHALEN-2-YL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2015-05-13 | — | — | EP | disclosed |
| US-8329880-B2 | Process for the preparation of naphthalen-2-yl-pyrazol-3-one intermediates useful in the synthesis of sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-12-11 | — | — | US | disclosed |
| CN-102066332-A | Process for the preparation of naphthalen-2-yl-pyrazol-3-one intermediates useful in the synthesis of sigma receptor inhibitors | ESTEVE LABOR DR | 2011-05-18 | — | — | CN | disclosed |
| US-20110071282-A1 | PROCESS FOR THE PREPARATION OF NAPHTHALEN-2-YL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-24 | — | — | US | disclosed |
| EP-2112139-A1 | Process for the preparation of naphthalen-2-yl-pyrazol-3-one intermediates useful in the synthesis of sigma receptor inhibitors | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071282-A1 | PROCESS FOR THE PREPARATION OF NAPHTHALEN-2-YL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTOR INHIBITORS | SIGMAR1, OPRK1, OPRM1 | MEN1 4479/4885KMT2A 3995/4885LMNA 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.